Biometrics and biometric-enabled decision support systems (DSS) have become a mandatory part of complex dynamic systems such as security checkpoints, personal health monitoring systems, autonomous robots, and epidemiological surveillance. Risk, trust, and bias (R-T-B) are emerging measures of performance of such systems. The existing studies on the R-T-B impact on system performance mostly ignore the complementary nature of R-T-B and their causal relationships, for instance, risk of trust, risk of bias, and risk of trust over biases. This paper offers a complete taxonomy of the R-T-B causal performance regulators for the biometric-enabled DSS. The proposed novel taxonomy links the R-T-B assessment to the causal inference mechanism for reasoning in decision making. of the R-T-B assessment in the DSS are demonstrated using the experiments of assessing the trust in synthetic biometric and the risk of bias in face biometrics. The paper also outlines the of the proposed approach beyond biometrics, including decision support for epidemiological surveillance such as for COVID-19 pandemics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545314 | PMC |
http://dx.doi.org/10.1109/ACCESS.2020.3015855 | DOI Listing |
BMC Med Ethics
January 2025
Faculty of Law, University of Montreal, Ch de la Tour, Montreal, QC, H3T 1J7, Canada.
Background: Considering the disruptive potential of AI technology, its current and future impact in healthcare, as well as healthcare professionals' lack of training in how to use it, the paper summarizes how to approach the challenges of AI from an ethical and legal perspective. It concludes with suggestions for improvements to help healthcare professionals better navigate the AI wave.
Methods: We analyzed the literature that specifically discusses ethics and law related to the development and implementation of AI in healthcare as well as relevant normative documents that pertain to both ethical and legal issues.
Leukemia
January 2025
Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival (PFS) and overall survival versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). In this post hoc analysis of clinically important subgroups in MAIA (median follow-up, 64.
View Article and Find Full Text PDFRoutine use of genetic data in healthcare is much-discussed, yet little is known about its performance in epidemiological models including traditional risk factors. Using severe COVID-19 as an exemplar, we explore the integration of polygenic risk scores (PRS) into disease models alongside sociodemographic and clinical variables. PRS were optimized for 23 clinical variables and related traits previously-associated with severe COVID-19 in up to 450,449 UK Biobank participants, and tested in 9,560 individuals diagnosed in the pre-vaccination era.
View Article and Find Full Text PDFSci Rep
January 2025
Pharmacy Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, England, UK.
Prescribing errors are a source of preventable harm in healthcare, which may be mitigated using Electronic Prescribing (EP) systems. Anyone who routinely prescribes medication could benefit from digitally assisted automated checks to identify whether a prescription should potentially not be allowed (e.g.
View Article and Find Full Text PDFJ Rheumatol
January 2025
Florenzo Iannone, Rheumatology Unit - Department of Precision and Regenerative Medicine of Jonian Area University of Bari, Bari, Italy.
Objective: Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU could reduce the incidence of PAH in a large SSc cohort from the SPRING registry.
Methods: Patients with SSc from the SPRING registry, meeting ACR/EULAR 2013 classification criteria with data on PAH onset, DU status, BOS exposure, and at least a one-year follow-up between 2015 and 2020, and no known PAH at baseline were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!